4D Molecular Therapeutics, Inc.FDMTEarnings & Financial Report
Nasdaq
NextMar 19, 2026
FDMT Q3 2025 Key Financial Metrics
Revenue
$90.0K
Gross Profit
N/A
Operating Profit
$-61.2M
Net Profit
$-56.9M
Gross Margin
N/A
Operating Margin
-67983.3%
Net Margin
-63195.6%
YoY Growth
2900.0%
EPS
$-1.01
Financial Flow
4D Molecular Therapeutics, Inc. Q3 2025 Financial Summary
4D Molecular Therapeutics, Inc. reported revenue of $90.0K for Q3 2025, with a net profit of $-56.9M (-63195.6% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $90.0K |
|---|---|
| Net Profit | $-56.9M |
| Gross Margin | N/A |
| Operating Margin | -67983.3% |
| Report Period | Q3 2025 |
4D Molecular Therapeutics, Inc. Annual Revenue by Year
4D Molecular Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $37.0K).
| Year | Annual Revenue |
|---|---|
| 2024 | $37.0K |
| 2023 | $20.7M |
| 2022 | $3.1M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $-18000 | $28000 | $5000 | $3000 | $1000 | $14000 | $15000 | $90000 |
| YoY Growth | -101.4% | -90.6% | -97.9% | -100.0% | 105.6% | -50.0% | 200.0% | 2900.0% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $339.9M | $629.9M | $620.1M | $604.0M | $560.4M | $515.7M | $473.6M | $424.0M |
| Liabilities | $32.1M | $29.3M | $31.8M | $51.1M | $49.8M | $46.0M | $52.7M | $55.0M |
| Equity | $307.8M | $600.6M | $588.3M | $552.9M | $510.6M | $469.7M | $420.9M | $369.0M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-24.6M | $-29.1M | $-30.2M | $-29.4M | $-45.9M | $-47.8M | $-43.4M | $-46.5M |